Abstract. The study of chest injuries which profoundly impact quality of life, life expectancy, disability rates, and mortality is of significant importance. In clinical research, the authors analyzed diagnostic results from 527 patients aged 18 to 85 with closed chest trauma, consisting of 82% men and 18% women. The study confirms
that traumatic chest injuries are severe conditions that necessitate strict adherence to well-defined diagnostic and treatment guidelines. It is advisable to utilize thoracoscopy and video-assisted thoracoscopy for managing hemothoraxes with small volumes of bleeding, as these minimally invasive techniques can enhance patient outcomes and reduce recovery times. The incorporation of advanced three-dimensional (3D) printing
technologies into medical practice for chest injuries is also recommended, as it can improve surgical
planning and enable personalized treatment strategies. Moreover, 3D printing can aid in the fabrication of patient-specific implants and prosthetics, thereby enhancing the effectiveness of reconstructive surgeries. Further research is needed on pharmacotherapy when using medications in accordance with the codes of the 11th revision of
the International Classification of Diseases, to optimize therapeutic efficacy. Additionally, an indepth study of the integrated ABC/VEN-analysis of drug prescriptions in pharmacotherapeutic regimens for thoracic trauma treatment dynamics in both inpatient and outpatient healthcare facilities is recommended. This could lead to better resource
allocation, improved patient care, and the development of more effective treatment protocols.
Emphasizing interdisciplinary collaborationamong surgeons, radiologists, and pharmacologists is crucial to advance the management of chest trauma, ensuring that patients receive comprehensive and holistic care throughout their
recovery process.
Keywords: quality of life, life expectancy, fatalities, trauma, chest, thoracoscopic surgery, thoracic injuries.

Abstract. For the first time in Ukraine, our team successfully  applied  extracorporeal  blood hyperthermia (EBH) within a closed-loop circuit to manage inflammatory conditions of the lungs and pleura. Controlled warming of autologous blood to 38°C and its subsequent reinfusion produced rapid, clinically  significant  reductions  in  exudative pleurisy,  pleural  empyema,  and  paracancerous inflammatory  lesions.  Earlier,  EBH  had  been 
incorporated  into  U.S.  military  field  protocols between  2003  and  2007,  and  it  is  now  formally 
included  in  therapeutic  guidelines  across  the United  States,  Canada,  New  Zealand,  multiple European nations, and several African healthcare systems.  Our  findings  corroborate  international data  showing  that  mild  systemic  hyperthermia enhances  phagocytic  activity,  improves microcirculation  within  the  pleural  cavity,  and accelerates  resorption  of  inflammatory  exudate while  maintaining  a  favorable  safety  profile.  No severe adverse events or hemodynamic instabilities were observed during or after the procedures in our 
cohort.  Beyond  its  direct  anti-inflammatory impact, EBH may potentiate antibiotic penetration into pleural tissues, offering a valuable adjunct in the  era  of  rising  antimicrobial  resistance.  Future multicenter  trials  with  larger  patient  populations and  comparative  cost-effectiveness  analyses  are warranted  to  refine  treatment  parameters  and confirm  long-term  benefits  of  this  promising modality. 
Keywords:  inflammatory  pulmonary  pathology, treatment, extracorporeal blood hyperthermia

Abstract. The healthcare sector is faced with the need to find new innovative and multidisciplinary approaches  for  the  prevention  and  treatment  of Covid, post-Covid, long-Covid, chronic, comorbid disorders. The results of 30 years of experience in the  use  of  halotherapy  in  the  treatment  of pulmonary pathology indicate that the authors of the article have established the optimal level of use of  halotherapy  in  pathological  pulmonary 
processes.  At  the  same  time,  clinical  experience provides evidence for the optimal method of using 
the halotherapy method in pulmonary nosologies. The  method  of  using  salt  therapy  in  exudative 
pleurisy, in fibrinous pleurisy, in fibrotic processes in  the  lungs  has  been  theoretically  substantiated, 
developed, and implemented in clinical practice. It has  been  proven  that  halotherapy  is  an  effective 
treatment  method  for  bronchial  asthma,  chronic obstructive  pulmonary diseases,  acute  respiratory 
viral infections, fibrinous and exudative pleurisy. The therapeutic effect of this method is observed only when using halogenerators with the ability to grind salt in the range of 1-5 microns. Halotherapy sessions  in  patients  with  bronchial  asthma  with mild  and  moderate  severity  lead  to  the development  of  nonspecific hyposensitization, which  in  turn  provides  long-term  remission  of attacks  and  reduces  the  need  for 
glucocorticosteroid  drugs.  Halotherapy  has  a confirmed immunomodulatory effect and activates local and T-cell immunity. It requires further study of  the  experience  of  halotherapy,  conducting marketing, pharmacoeconomic  and  comparative analysis. 
Keywords:  halotherapy,  pulmonary  pathologies, thoracic  pathology,  bronchial  asthma,  fibrinous 
pleurisy, post-covid syndrome, patient.